Your browser doesn't support javascript.
loading
Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl, Suzy; Popovic, Marina; de la Rochefordiere, Anne; Girard, Elodie; Dureau, Sylvain; Mandic, Aljosa; Koprivsek, Katarina; Samet, Nina; Craina, Marius; Margan, Madalin; Samuels, Sanne; Zijlmans, Henry; Kenter, Gemma; Hillemanns, Peter; Dema, Sorin; Dema, Alis; Malenkovic, Goran; Djuran, Branislav; Floquet, Anne; Garbay, Delphine; Guyon, Frédéric; Colombo, Pierre Emmanuel; Fabbro, Michel; Kerr, Christine; Ngo, Charlotte; Lecuru, Fabrice; Campo, Eleonor Rivin Del; Coutant, Charles; Marchal, Frédéric; Mesgouez-Nebout, Nathalie; Fourchotte, Virginie; Feron, Jean Guillaume; Morice, Philippe; Deutsch, Eric; Wimberger, Pauline; Classe, Jean-Marc; Gleeson, Noreen; von der Leyen, Heiko; Minsat, Mathieu; Dubot, Coraline; Gestraud, Pierre; Kereszt, Attila; Nagy, Istvan; Balint, Balazs; Berns, Els; Jordanova, Ekaterina; Saint-Jorre, Nicolas de; Savignoni, Alexia; Servant, Nicolas; Hupe, Philippe.
Afiliação
  • Scholl S; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France. Electronic address: suzy.scholl@curie.fr.
  • Popovic M; Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.
  • de la Rochefordiere A; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Girard E; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Dureau S; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Mandic A; Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.
  • Koprivsek K; Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.
  • Samet N; Publica Institutul Oncologic, Republic of Moldova.
  • Craina M; University of Medicine and Pharmacy "Victor Babeș", Romania.
  • Margan M; University of Medicine and Pharmacy "Victor Babeș", Romania.
  • Samuels S; Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC and The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Zijlmans H; Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC and The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Kenter G; Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC and The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Hillemanns P; Hannover Medical School, Germany.
  • Dema S; University of Medicine and Pharmacy "Victor Babeș", Romania.
  • Dema A; University of Medicine and Pharmacy "Victor Babeș", Romania.
  • Malenkovic G; Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.
  • Djuran B; Gynecologic Oncology Department Clinic for Operative Oncology, Institute of Oncology of Vojvodina, Serbia.
  • Floquet A; Chirurgie onco-gynécologique and Oncology, Institut Bergonié, Centre Régional de Lutte contre le Cancer Bordeaux-Aquitaine, France.
  • Garbay D; Chirurgie onco-gynécologique and Oncology, Institut Bergonié, Centre Régional de Lutte contre le Cancer Bordeaux-Aquitaine, France.
  • Guyon F; Chirurgie onco-gynécologique and Oncology, Institut Bergonié, Centre Régional de Lutte contre le Cancer Bordeaux-Aquitaine, France.
  • Colombo PE; Centre Val d'Aurelle, France.
  • Fabbro M; Centre Val d'Aurelle, France.
  • Kerr C; Centre Val d'Aurelle, France.
  • Ngo C; Service de chirurgie cancérologique gynécologique et du sein, Hôpital Européen Georges Pompidou, APHP et faculté de médecine, Université Paris Descartes, France.
  • Lecuru F; Service de chirurgie cancérologique gynécologique et du sein, Hôpital Européen Georges Pompidou, APHP et faculté de médecine, Université Paris Descartes, France.
  • Campo ERD; Department of Radiation Oncology, Tenon University Hospital, Hôpitaux Universitaires Est Parisien, Sorbonne University Medical Faculty, Paris, France.
  • Coutant C; Centre Georges François Leclerc, France.
  • Marchal F; Département de chirurgie, CRAN, UMR 7039, Université de Lorraine, CNRS, Institut de Cancérologie de Lorraine, 6 avenue de Bourgogne - CS 30519 54519, Vandoeuvre-les-Nancy Cedex, France.
  • Mesgouez-Nebout N; Institut de cancérologie de l'Ouest - site Paul Papin (ICO) 15, Rue André Boquel, 49055 Angers, France.
  • Fourchotte V; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Feron JG; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Morice P; Gustave Roussy, France.
  • Deutsch E; Gustave Roussy, France.
  • Wimberger P; Department of Gynecology and Obstetrics, Universitätsklinikum Carl Gustav Carus; an der Technischen Universität Dresden, Fetscherstraße 74, 01307 Dresden, Germany.
  • Classe JM; René Gauducheau, France.
  • Gleeson N; St James/Trinity College, Ireland.
  • von der Leyen H; Hannover Clinical Trial Center GmbH, Germany.
  • Minsat M; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Dubot C; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Gestraud P; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Kereszt A; SeqOmics Biotechnology Ltd, Vallalkozok utja 7, Morahalom, Hungary.
  • Nagy I; SeqOmics Biotechnology Ltd, Vallalkozok utja 7, Morahalom, Hungary.
  • Balint B; SeqOmics Biotechnology Ltd, Vallalkozok utja 7, Morahalom, Hungary.
  • Berns E; Erasmus MC, The Netherlands.
  • Jordanova E; Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC and The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
  • Saint-Jorre N; Quanticsoft, France.
  • Savignoni A; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Servant N; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
  • Hupe P; Institut Curie, PSL Research University, Department of Drug Development and Innovation, France.
EBioMedicine ; 43: 253-260, 2019 May.
Article em En | MEDLINE | ID: mdl-30952619
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Neoplasias do Colo do Útero / Epigênese Genética / Classe I de Fosfatidilinositol 3-Quinases Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: EBioMedicine Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Biomarcadores Tumorais / Neoplasias do Colo do Útero / Epigênese Genética / Classe I de Fosfatidilinositol 3-Quinases Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: EBioMedicine Ano de publicação: 2019 Tipo de documento: Article